New kidney drug B007 takes on cyclosporine in major trial
NCT ID NCT06470191
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug, B007, against the standard treatment cyclosporine for people with primary membranous nephropathy, a kidney disease that causes protein leakage. About 216 adults with confirmed disease and adequate kidney function will be randomly assigned to receive either B007 or cyclosporine. The main goal is to see if B007 leads to more remissions (improvement) and has fewer side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY MEMBRANOUS NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Affiliated Hospital of Nantong University
RECRUITINGNantong, China
-
Beijing Tsinghua Changgung Hospital
RECRUITINGBeijing, China
-
Northern Jiangsu People's Hospital
RECRUITINGYangzhou, China
-
Northern Theater Command General Hospital
RECRUITINGShenyang, China
-
Peking University Shenzhen Hospital
RECRUITINGShenzhen, China
-
Peking university first hospital
RECRUITINGBeijing, China
-
Renmin Hospital of Wuhan University
RECRUITINGWuhan, China
-
Shandong Provincial Hospital
RECRUITINGJinan, China
-
Shengjing Hospital affiliated to China Medical University
RECRUITINGShenyang, China
-
Sir Run Run Shaw Hospital , affiliated with the Zhejiang University School of Medicine
RECRUITINGHangzhou, China
-
The Affiliated Hospital of Qingdao University
RECRUITINGQingdao, China
-
The First Affiliated Hospital of Guangxi Medical University
RECRUITINGNanning, China
-
The First Affiliated Hospital, Sun Yat-sen University
RECRUITINGGuangzhou, China
-
The First Affiliated Hospital, Zhejiang University School of Medicine
RECRUITINGHangzhou, China
-
The First People's Hospital of Zigong
RECRUITINGZigong, China
-
The Second Affiliated Hospital of Xingtai Medical college
RECRUITINGXingtai, China
-
The Second Norman Bethune Hospital of Jilin University
RECRUITINGChangchun, China
-
Wuxi People's Hospital
RECRUITINGWuxi, China
-
Xi'an Daxing Hospital
RECRUITINGXi'an, China
-
Yantai Yuhuangding Hospital
RECRUITINGYantai, China
-
Zhujiang Hospital of Southern Medical University
RECRUITINGGuangzhou, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can engineered immune cells tackle a tough kidney disease?
- Can a smarter antibody outsmart a kidney disease that resists standard treatment?
- Can engineered immune cells tame autoimmune kidney disease?
- Can a pill calm the immune attack on kidneys?
- Can a gene-silencing drug calm overactive complement in kidney disease?
- New gel could outperform standard therapy for kidney disease